The Kenox Team is a group of highly motivated professionals committed to bringing superior drug products to patients around the world. Empowered by experience working with drug formulation and delivery, together with our industry savvy, we are fully equipped to deliver results and achieve goals in all our projects and initiatives.
Dr. Velaga is a highly accomplished and internationally recognized pharmaceutical professional with over 18 years of academic and industrial experience in the areas of solid-state chemistry, solubilization technologies, particle engineering, and the development of specialized dosage forms, including oral films and aerosol-based drug products. Dr. Velaga has proven himself a strong leader, having successfully built and led teams of highly skilled and motivated scientists and scholars. He has established strong business and professional relationships with pioneering scientists, universities, and pharmaceutical companies in a number of countries around the world. He brings his years of experience in drug-product development, innovative research, project management, business development, and strategy to Kenox.
Dr. Dontineni is an Internal Medicine Specialist, currently pursuing a fellowship in infectious diseases. He has received professional recognition for his clinical and academic accomplishments throughout his medical education and years as a practicing physician. He has been treating patients with allergies, asthma, COPD, and other lung diseases for over 23 years, and takes great pride and satisfaction in improving their lives through innovations in healthcare. With his wealth of clinical experience, Dr Dontineni is well-qualified to spearhead Kenox product development and strategy.
Mr. Stadermann is a Chemical Engineer and aerosol-based product-development scientist with over 12 years of experience in the development and manufacturing of pMDIs and DPIs. He has strong technical expertise in the development, submission, and patent litigations of inhalation drug substances and drug products. He has a proven track record in both generic and innovative development at a number of prestigious pharmaceutical companies, including Teva, Solvay, and Merck. Mr. Stadermann has authored CMC sections for various clinical and commercial inhalation products, and has directly engaged with global regulatory authorities (EMEA, US, JP, LATAM, and RoW). Among his key achievements are the successful development and approval of budesonide/formoterol and fluticasone/salmeterol products.
We also consult with industry veterans on various aspects of drug product development.